Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy

Toshiaki Sendo, Naoko Sakai, Yoshinori Itoh, Hiroaki Ikesue, Hiroaki Kobayashi, Toshio Hirakawa, Hitoo Nakano, Ryozo Oishi

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)


Hypersensitivity reaction (HSR) is still a major concern during cancer chemotherapy with paclitaxel. In the present study, we investigated retrospectively the incidence of HSRs to paclitaxel and the risk factors in 105 patients (553 courses) who received adjuvant chemotherapy (paclitaxel and carboplatin) for ovarian cancer. Moderate to severe HSRs that led to cessation or discontinuation of the chemotherapy, including respiratory distress and hypotension, were observed in 14 patients (13.3%) and 16 courses (2.9%), regardless of the use of conventional premedication with glucocorticoid, and histamine H1 and H2 antagonists. The incidence of HSRs to paclitaxel in patients with ovarian cancer seemed to be considerably higher than those reported by other investigators in patients with other carcinomas such as non-small-cell lung cancer and breast cancer. Four risk factors were identified: (1) history of mild dermal reactions such as facial flushing and urticaria in previous courses, (2) presence of respiratory dysfunction, (3) obesity (body mass index >25), and (4) postmenopausal at the time of ovariectomy. The incidence of hypersensitivity increased linearly as the number of risk factors increased (r=0.992, P=0.008). It is likely that disappearance of the estrous cycle facilitates the occurrence of HSRs to paclitaxel.

Original languageEnglish
Pages (from-to)91-96
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Issue number1
Publication statusPublished - Jul 2005
Externally publishedYes


  • Hypersensitivity reaction
  • Ovarian cancer
  • Paclitaxel
  • Risk factor

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy'. Together they form a unique fingerprint.

Cite this